Esketamine for treatment resistant depression is not recommended by NICEBMJ 2020; 368 doi: https://doi.org/10.1136/bmj.m329 (Published 28 January 2020) Cite this as: BMJ 2020;368:m329
- Elisabeth Mahase
- The BMJ
An esketamine nasal spray may not be made available on the NHS for patients with treatment resistant depression because of uncertainties over its clinical and cost effectiveness, says draft guidance from the National Institute for Health and Care Excellence.1
NICE reviewed the effectiveness of esketamine in combination with a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor for adults with treatment resistant depression that have not responded to at least two different antidepressants in the current moderate to severe depressive episode.
It said that …